Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Cabozantinib beats placebo in neuroendocrine tumors across the board. A subgroup analysis of the phase 3 CABINET trial found that cabozantinib significantly improved progression-free survival in patients with both functional and nonfunctional neuroendocrine tumors (NETs). The findings reinforce cabozantinib as a viable treatment option regardless of a tumor's hormone-secreting status.
Cabozantinib continues to impress in neuroendocrine tumors. A subgroup analysis from the phase 3 CABINET trial, presented at the 2026 NANETS Multidisciplinary NET Medical Symposium, confirmed that the drug's progression-free survival (PFS) benefit holds up whether patients have hormone-secreting (functional) or non-secreting (nonfunctional) NETs — including both extrapancreatic and pancreatic subtypes.
The analysis zeroed in on 253 patients split across the two subgroups, and the results were clear: cabozantinib outperformed placebo in both. The safety profile was also consistent with what's been seen in the broader trial, with hypertension being the most notable grade 3+ adverse event in both groups.
By the Numbers:
Why it matters: NETs are a heterogeneous group of tumors, and treatment decisions can be complicated by whether tumors are hormonally active. These findings suggest clinicians don't need to factor in hormone functional status when considering cabozantinib — broadening its potential use across a wider NET patient population.
